Human immunodeficiency virus [HIV] disease. Human immunodeficiency virus [HIV] disease resulting in other conditions
Conditions
Interventions
Intervention 1: Interventional group: cyproheptadine, oral tablet 4 mg, 2 tablets at night for 1 week.cyproheptadine, oral tablet 4 mg, 3 tablets at night for other 3 weeks. Intervention 2: Control gr
Treatment - Drugs
Placebo
Interventional group: cyproheptadine, oral tablet 4 mg, 2 tablets at night for 1 week.cyproheptadine, oral tablet 4 mg, 3 tablets at night for other 3 weeks
Control group: cyproheptadine placebo, oral tablet 4 mg, 2 tablets at night for 1 week.cyproheptadine placebo, oral tablet 4 mg, 3 tablets at night for other 3 weeks
Sponsors
Vice-Chancellor for Research,Tehran University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with HIV-1 infection, older than 18 years who are scheduled to receive an efavirenz-containing treatment Exclusion criteria: Pervious treatment with antiretroviral drugs including efavirenz, pregnancy, use of other medications that be effective on patient‘s mood such as methadone and having major psychiatric disorders like depression at the beginning of this study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropsychiatric effects of efavirenz. Timepoint: Before intevention, 4 weeks after intervention. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Appetite. Timepoint: Before intevention, 4 weeks after intervention. Method of measurement: Questionnaire.;Weight. Timepoint: Before intevention, 4 weeks after intervention. Method of measurement: Weight scale. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed